Filter Results:
(4)
Show Results For
- All HBS Web
(4)
- Research (3)
- Faculty Publications (2)
Show Results For
- All HBS Web
(4)
- Research (3)
- Faculty Publications (2)
Page 1 of 4
Results
- December 2014 (Revised October 2017)
- Case
Social Business at Novartis: Arogya Parivar
By: Michael E. Porter, Mark R. Kramer and David Lane
Late in 2013, Novartis CEO Joseph Jimenez was considering whether or how to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India while expanding access to medicine and health information to millions of... View Details
Keywords: Shared Value; India; Kenya; Vietnam; Novartis; Arogya Parivar; Social Business; Multinational Firms and Management; Competitive Advantage; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Viet Nam; Kenya; India
Porter, Michael E., Mark R. Kramer, and David Lane. "Social Business at Novartis: Arogya Parivar." Harvard Business School Case 715-411, December 2014. (Revised October 2017.)
- October 2018
- Teaching Note
Social Business at Novartis: Arogya Parivar
By: Mark R. Kramer and Michael E. Porter
- 18 Feb 2015
- First Look
First Look: February 18
which brought together multiple organizations to enhance agricultural development in rural regions. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/715402-PDF-ENG Harvard Business School Case 715-411 Social Business at Novartis: View Details
Keywords: Sean Silverthorne
- Web
Published CSV Cases - Institute For Strategy And Competitiveness
management began drafting the company's sustainability plan for 2015 and beyond, CEO Andrew Liveris confronted the question of whether to maintain, modify or terminate the BWC program. SOCIAL BUSINESS AT NOVARTIS: AROGYA View Details